Aggregated from the cited literature below. We summarize sources — we don't author claims.
Sermorelin is discussed in the provided sources as a growth hormone secretagogue/growth hormone releasing hormone (GHRH) synthetic analog that is considered among compounds affecting GH/IGF-1 signaling pathways, and it also appears in research focused on doping detection and analytical stability/detection methods. (PMIDs: 41490200, 41966639, 34665524, 32257855, 37806509, 36787346)
Mechanism (as reported)
Research described sermorelin as part of the growth hormone secretagogues, reported to be GH and IGF-1 stimulators, and discussed in the context of activating IGF-1 signaling and pathways related to tissue repair/satellite cell involvement. (PMIDs: 41490200, 41966639, 32257855, 34665524)
Key findings (each cites a source)
A review on therapeutic peptides in orthopaedics lists sermorelin among growth hormone secretagogues that are reported to activate IGF-1 signaling and satellite cell repair, and it notes that there is a lack of clinical trials despite promising preclinical studies. [PMID 41490200]
A narrative review on peptide therapies for musculoskeletal injuries in sports medicine includes sermorelin among prominent approved/unapproved peptides marketed direct to patients and states that rigorous human safety data are scarce for many unapproved peptides. [PMID 41966639]
Research investigated in vitro metabolism and detection of GHRH synthetic analogs including sermorelin in fortified urine, identifying multiple metabolites and using them to develop a sensitive LC-MS/MS method for detection to support evidence of GHRH administration. [PMID 34665524]
A review addressing growth hormone secretagogues in body composition discussed sermorelin as a GH and IGF-1 stimulator and described that data on clinical effects remain limited, creating opportunities for future investigation. [PMID 32257855]
Analytical work on in-house standards derived from doping peptides evaluated enzymatic and serum stability of sermorelin fragments (e.g., Sermorelin (1-11), (13-20), (22-29)) and reported that selected sermorelin fragment(s) (including Sermorelin (22-29)) can be considered stable to enzyme and blood treatment and used as internal standards in quantification workflows. [PMID 37688464]
A validated urine method for detecting GHRH analogs reported inclusion of sermorelin forms (including sermorelin (GRF 1-29) and sermorelin (3-29)-NH2) using a triple quadrupole UHPLC/MS-MS approach with SPE, describing sensitivity and performance characteristics aligned with anti-doping laboratory screening requirements. [PMID 37806509]
A capillary electrophoresis study proposed analysis of GHRH analogs including sermorelin (and CJC-1293) and reported chiral separation of enantiomeric/basic analogs and application to urine after desalting, with method-sensitivity results reported as limits of detection. [PMID 36787346]
Vendor test rankings (7)
Vendors ranked by their independent third-party test grade for Sermorelin, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.3% across 186 tests. Not our verdict.
Prakash A, Goa KL · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999 · PMID 18031173
FAQ
What is Sermorelin?
Sermorelin (Sermorelina, 86168-78-7, Sermoreline) is classified under ghrh analogs, which has been withdrawn from approved use. Research goals associated with it include gh axis support.
Is Sermorelin FDA-approved?
Sermorelin has been withdrawn from approved use.
What does the research on Sermorelin say?
peptideone aggregates 9 references from PubMed for Sermorelin. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.